Comparison Of Cancer Survival Rates

Survival rates for metastatic colon cancer much improved

This is the conclusion of the latest EUROCARE-5 reports for 1999-2007, covering more than 50 per cent of the adult and 77 per cent of the childhood population of Europe. It says cancer survival still varies widely between European countries, despite major improvements in cancer diagnosis and treatment during the first decade of the 21st Century. It should be borne in mind that the Irish figures pre-dated the implementation of the National Cancer Control Policy. The findings, published in The Lancet Oncology, analysed data from cancer registries covering all or part of 29 countries to compare five-year survival from diagnosis for more than nine million adults diagnosed between 2000 and 2007. The 29 countries were grouped into five regions, with England, Ireland, Northern Ireland, Scotland and Wales forming one region, titled the UK and Ireland. Nordic countries (with the exception of Denmark), central European countries such as Austria, Belgium, France, Germany, Switzerland and the Netherlands, and some countries in southern Europe, particularly Italy, Portugal, and Spain, have the best survival for most cancers. Survival for the whole of Europe increased from 78.4 per cent in 1999-2001 to 82.4 per cent in 2005-2007. This increase was steepest in Eastern Europe and the UK and Ireland, so the survival gap between these regions and Europe decreased. Survival in the UK and Ireland was intermediate for rectal cancer, breast cancer, prostate cancer, skin melanoma and non-Hodgkins lymphoma, but low for kidney, stomach, ovarian, colon and lung cancers. For most countries, five-year survival for breast cancer (women only) was fairly close to the European mean. Survival of women aged 75 years and older was particularly low in the UK and Ireland, although it had increased steeply since 2005. Kidney cancer survival was lowest for the oldest patients in the UK and Ireland. Survival for lung cancer in the UK and Ireland was much lower than for other regions for all periods, although results for lung cancer in some regions (central and eastern Europe) might be affected by overestimation, according to the study. However, Irish rates were 11.8 per cent compared to the regions rate of 9 per cent. Irish five-year survival rates for prostate cancer at 85.6 per cent were higher than the regions figure of 80. 6 per cent. Five-year survival for kidney cancer in Ireland was 51.8 per cent compared to the region figure of 47.6 per cent and the rate for non-Hodgkins lymphoma at 67 per cent, compared to the regions figure of 57.4 per cent. For stomach cancer, five-year survival, as calculated from the first dataset, was poor, with lowest survival in Eastern Europe and the UK and Ireland. via this link

Only 8% of patients survived five years with the disease in 1990 comparedwith 30% of people diagnosed with the disease after 2004. The study, published today in the Journal of Clinical Oncology , suggests that new chemotherapy treatments and biological agents, along with improvements in surgery to remove tumors from the liver, have resulted in big gains in survival. The study is the first to examine survival rates for metastatic colorectal cancer in the last 20 years. The authors of the study say median survival is now more than 30 months, comparedwith eight months for patients diagnosed before 1990. The study also compared the effects of surgery and chemotherapy on survival rates. Since 2000, more patients undergo surgery to remove parts of the liver invaded by cancer. They found that liver resection surgery led to increased survival statistics, as did the availability of several new cancer medications beginning in 2004. ". . .The degree and rapidity of the improvement is of a magnitude that is rarely seen in metastatic cancers," Dr. Scott Kopetz, an assistant professor at M.D. Anderson Cancer Center's Department of Gastrointestinal Medical Oncology and the study's lead author, said in a news release. they said